Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caitlin Costello

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2022
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, et al.
Blood Cancer Journal|July 8, 2024
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFINAjai Chari, Jonathan L Kaufman, Jacob Laubach, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 10, 2016
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016Kenneth C Anderson, Melissa Alsina, Djordje Atanackovic, et al.
Future Oncology (London, England)|October 25, 2024
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myelomaPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2017
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Melissa Alsina, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 11, 2015
Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in OncologyKenneth C Anderson, Melissa Alsina, Djordje Atanackovic, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 8, 2019
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020Shaji K Kumar, Natalie S Callander, Jens Hillengass, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 4, 2018
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018Shaji K Kumar, Natalie S Callander, Melissa Alsina, et al.
The Lancet. Haematology|September 14, 2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Blood|April 24, 2020
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialPeter M Voorhees, Jonathan L Kaufman, Jacob Laubach, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2022
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, et al.
Blood Cancer Journal|July 8, 2024
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFINAjai Chari, Jonathan L Kaufman, Jacob Laubach, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 10, 2016
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016Kenneth C Anderson, Melissa Alsina, Djordje Atanackovic, et al.
Future Oncology (London, England)|October 25, 2024
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myelomaPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2017
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Melissa Alsina, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 11, 2015
Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in OncologyKenneth C Anderson, Melissa Alsina, Djordje Atanackovic, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 8, 2019
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020Shaji K Kumar, Natalie S Callander, Jens Hillengass, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 4, 2018
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018Shaji K Kumar, Natalie S Callander, Melissa Alsina, et al.
The Lancet. Haematology|September 14, 2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Blood|April 24, 2020
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialPeter M Voorhees, Jonathan L Kaufman, Jacob Laubach, et al.
Pageof 6